Montana L. Sievert

Montana L. Sievert

Auto-generated profile, based on publicly available information

Montana L. Sievert

Department of Molecular Microbiology and Immunology Johns Hopkins Bloomberg School of Public Health 615N. Wolfe Street, E5132 MD 21205 Baltimore USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
JDJan‐Niklas Dienemann
Jan‐Niklas Dienemann
SCShu‐Yu Chen
Shu‐Yu Chen
MHManuel Hitzenberger
Manuel Hitzenberger
MSMontana L. Sievert
Montana L. Sievert
SHStephan M. Hacker
Stephan M. Hacker
SSStephan A. Sieber
Stephan A. Sieber
The development of novel anti‐infectives requires unprecedented strategies targeting pathways which are solely present in pathogens but absent in humans. Following this principle, we developed inhibitors of lipoic acid (LA) salvage, a crucial pathway for the survival of LA auxotrophic bacteria and parasites but non‐essential in human cells. An LA‐based probe was selectively transferred onto substrate proteins via lipoate protein ligase (LPL) in intact cells, and their binding sites were determined by mass spectrometry. Probe labeling served as a proxy of LPL activity, enabling in situ screenings for cell‐permeable LPL inhibitors. Profiling a focused compound library revealed two substrate analogs (LAMe and C3) as inhibitors, which were further validated by binding studies and co‐crystallography. Importantly, LAMe exhibited low toxicity in human cells and achieved killing of Plasmodium falciparum in erythrocytes with an EC50 value of 15 μM, making it the most effective LPL inhibitor reported to date.

6 May 2025 in Journal of Molecular Biology
Verified
Journal Article
Closed access
RERubayet Elahi
Rubayet Elahi
SMSebastian Mesones Mancilla
Sebastian Mesones Mancilla
MSMontana L. Sievert
Montana L. Sievert
LDLuciana Ribeiro Dinis
Luciana Ribeiro Dinis
OAOpeoluwa Adewale-Fasoro
Opeoluwa Adewale-Fasoro
SPSean T. Prigge
Sean T. Prigge

1 December 2025 in bioRxiv
Verified
Preprint
Open access
KRKrithika Rajaram
Krithika Rajaram
MSMontana L. Sievert
Montana L. Sievert
RERubayet Elahi
Rubayet Elahi
LDLucas B. Dillard
Lucas B. Dillard
JBJames Blauwkamp
James Blauwkamp
SPSean T. Prigge
Sean T. Prigge
The malaria parasite Plasmodium falciparum depends entirely on de novo pyrimidine synthesis, as it is unable to salvage these essential nucleotides. This reliance makes the pyrimidine biosynthesis pathway a compelling target for antimalarial drugs, with several inhibitors targeting its rate-limiting enzyme, dihydroorotate dehydrogenase ( Pf DHODH), already in clinical development. In this study, we investigated the roles of three other pathway enzymes – aspartate transcarbamoylase ( Pf ATC), carbamoyl phosphate synthetase II ( Pf CPSII), and dihydroorotase ( Pf DHO). Pf ATC features a unique N-terminal extension predicted to serve as an apicoplast trafficking peptide. However, using antibodies against the native protein and an epitope-tagged version, we found no evidence of apicoplast localization. Knockdown of Pf ATC expression proved lethal and could not be rescued by an apicoplast metabolic bypass. Complementation assays further revealed that truncation of the N-terminal domain impaired parasite growth, suggesting that this region is important for Pf ATC function or stability in vivo . Pf CPSII, which harbors large Plasmodium -specific insertions between its catalytic domains, was likewise found to be essential for parasite proliferation. To assess the role of Pf DHO, we engineered parasites to salvage uracil via heterologous expression of a yeast enzyme. Deletion of Pf DHO in this parasite line resulted in uracil auxotrophy, confirming the enzyme’s essential function in pyrimidine synthesis. Together, these findings reveal multiple vulnerable nodes within the pyrimidine biosynthesis pathway. AUTHOR SUMMARY: Nucleotides are central metabolites that serve as building blocks for DNA and RNA, act as key energy carriers, and function as cofactors or regulators in several metabolic pathways. To satisfy these diverse demands, most organisms rely on both nucleotide salvage and de novo synthesis. The malaria parasite Plasmodium falciparum acquires purine nucleotides from the host but lacks the capacity to salvage pyrimidines, making de novo pyrimidine synthesis essential. Several enzymes in this pathway differ from their human counterparts in sequence, domain architecture, and evolutionary origin, enhancing their potential as selective drug targets. Dihydroorotate dehydrogenase (PfDHODH), the fourth enzyme in the pathway, has already been validated as an antimalarial target. Here, we systematically examined upstream enzymes using molecular genetic approaches. Each proved essential for asexual blood-stage parasite survival, with the Plasmodium -specific N-terminal extension of aspartate carbamoyltransferase ( Pf ATC) required for optimal growth. The introduction of a yeast uracil salvage enzyme rescued parasites depleted of these biosynthetic enzymes, demonstrating that their essential functions are confined to pyrimidine production and that their distinctive structural features do not support additional metabolic roles. In summary, these results delineate additional enzymatic steps in this important metabolic pathway that warrant continued investigation from both biological and translational angles.

26 June 2023 in Angewandte Chemie
Verified
Journal Article
Open access
JDJan‐Niklas Dienemann
Jan‐Niklas Dienemann
SCShu‐Yu Chen
Shu‐Yu Chen
MHManuel Hitzenberger
Manuel Hitzenberger
MSMontana L. Sievert
Montana L. Sievert
SHStephan M. Hacker
Stephan M. Hacker
SSStephan A. Sieber
Stephan A. Sieber
Die Entwicklung neuer Antiinfektiva erfordert innovative Strategien zur gezielten Ausnutzung von Stoffwechselwegen in Krankheitserregern, die in menschlichen Zellen abwesend sind. Basierend auf diesem Prinzip haben wir Hemmstoffe der Liponsäure (LA) Wiederverwertung entwickelt, einem entscheidenden Stoffwechselweg für das Überleben von LA‐auxotrophen Bakterien und Parasiten, der jedoch in menschlichen Zellen nicht essentiell ist. Eine auf LA basierende Sonde wurde selektiv über die Lipoatproteinligase (LPL) auf Substratproteine in intakten Zellen übertragen, und ihre Bindungsstellen wurden mittels Massenspektrometrie bestimmt. Die Intensität der Markierung mit der Sonde diente als Maß für die Aktivität von LPL und ermöglichte intrazelluläre Selektion für zellpermeable LPL‐Hemmer. Das Testen einer vorselektierten Substanzbibliothek ergab zwei Substratanaloga (LAMe und C3) als Hemmstoffe, die durch Bindungsstudien und Co‐Kristallographie weiter validiert wurden. Bemerkenswert ist, dass LAMe eine geringe Toxizität in menschlichen Zellen aufwies und eine Abtötung von Plasmodium falciparum in Erythrozyten mit einem EC50‐Wert von 15 μM erreichte, was diesen Stoff zum bisher wirksamsten LPL‐Hemmer macht, der jeher berichtet wurde.

29 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAlexis Mann
Alexis Mann
MSMontana Sievert
Montana Sievert
RERubayet Elahi
Rubayet Elahi
STShivendra G. Tewari
Shivendra G. Tewari
KRKrithika Rajaram
Krithika Rajaram
SPSean T. Prigge
Sean T. Prigge
Plasmodium falciparum ATP4 mutations A211V and G223R allow parasites to survive the lethal effects of antimalarials PA21A092 (PA92) and cipargamin (CIP), respectively. An A211V mutant line (Dd2 A211V ) treated with PA92 showed enhanced levels of lipid production, which prompted the idea that components of the phospholipid biosynthesis pathway could be involved in the survival mechanism of Pf ATP4 mutant parasites. As phosphatidylserine synthase ( Pf PSS) is the only enzyme that produces phosopholipid phosphatidylserine (PS) in P. falciparum parasites, we hypothesized that Pf PSS is both essential for parasite survival and that reduced PfPSS expression would cause resistant Pf ATP4 mutant parasites to become susceptible to PA92 or CIP. We created a CIP-resistant G223R mutant line (Dd2 G223R ) via CRISPR-Cas9 and integrated a conditional Pf PSS knockdown construct into a Dd2 A211V (↓PSS-Dd2 A211V ) and our Dd2 G223R line (↓PSS-Dd2 G223R ). We treated these knockdown lines with PA92 or CIP to determine the half-maximal effective concentration (EC 50 ) of each antimalarial with normal or reduced Pf PSS levels. While we found that Pf PSS is essential for parasite survival, we did not find any significant alterations to the EC 50 values of PA92 or CIP based on the reduced levels of Pf PSS in our mutant lines. Although Pf PSS does not appear to be involved, other components of the phospholipid production pathway could still affect the resistance mechanism of Pf ATP4 mutations. Identification of novel targets to counteract the mechanism by which Pf ATP4 mutant parasites resist lethal drug effects is crucial for the successful application of antimalarials in endemic countries where resistance is on the rise.